Trial · NCT00650104
Results by group111
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 111
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Unified Parkinson's Disease (PD) Rating Scale (UPDRS) Total Activities of Daily Living Scores (Intent-to-Treat Population) | Ropinirole XL | Screening, n=83 | 9.4 | Standard Deviation 5.14 | points on a scale |
| Unified Parkinson's Disease (PD) Rating Scale (UPDRS) Total Activities of Daily Living Scores (Intent-to-Treat Population) | Ropinirole XL | Up-titration (Week 4), n=64 | 8.9 | Standard Deviation 4.60 | points on a scale |
| Unified Parkinson's Disease (PD) Rating Scale (UPDRS) Total Activities of Daily Living Scores (Intent-to-Treat Population) | Ropinirole XL | LTT, Month 3, n=76 | 8.2 | Standard Deviation 5.34 | points on a scale |
| Unified Parkinson's Disease (PD) Rating Scale (UPDRS) Total Activities of Daily Living Scores (Intent-to-Treat Population) | Ropinirole XL | LTT, Month 9, n=72 | 8.1 | Standard Deviation 5.03 | points on a scale |
| Unified Parkinson's Disease (PD) Rating Scale (UPDRS) Total Activities of Daily Living Scores (Intent-to-Treat Population) | Ropinirole XL | LTT, Month 15, n=67 | 9.0 | Standard Deviation 5.83 | points on a scale |
| Unified Parkinson's Disease (PD) Rating Scale (UPDRS) Total Activities of Daily Living Scores (Intent-to-Treat Population) | Ropinirole XL | LTT, Month 21, n=63 | 8.6 | Standard Deviation 5.01 | points on a scale |
| Unified Parkinson's Disease (PD) Rating Scale (UPDRS) Total Activities of Daily Living Scores (Intent-to-Treat Population) | Ropinirole XL | LTT, Month 27, n=58 | 9.3 | Standard Deviation 5.59 | points on a scale |
| Unified Parkinson's Disease (PD) Rating Scale (UPDRS) Total Activities of Daily Living Scores (Intent-to-Treat Population) | Ropinirole XL | LTT, Month 33, n=53 | 10.3 | Standard Deviation 6.14 | points on a scale |
| Unified Parkinson's Disease (PD) Rating Scale (UPDRS) Total Activities of Daily Living Scores (Intent-to-Treat Population) | Ropinirole XL | LTT, Month 39, n=19 | 10.5 | Standard Deviation 6.74 | points on a scale |
| Unified Parkinson's Disease (PD) Rating Scale (UPDRS) Total Activities of Daily Living Scores (Intent-to-Treat Population) | Ropinirole XL | LTT, Month 45, n=18 | 9.3 | Standard Deviation 4.47 | points on a scale |
| Unified Parkinson's Disease (PD) Rating Scale (UPDRS) Total Activities of Daily Living Scores (Intent-to-Treat Population) | Ropinirole XL | LTT, Month 51, n=19 | 10.1 | Standard Deviation 6.07 | points on a scale |
| Unified Parkinson's Disease (PD) Rating Scale (UPDRS) Total Activities of Daily Living Scores (Intent-to-Treat Population) | Ropinirole XL | LTT, Month 57, n=20 | 10.4 | Standard Deviation 5.80 | points on a scale |
| Unified Parkinson's Disease (PD) Rating Scale (UPDRS) Total Activities of Daily Living Scores (Intent-to-Treat Population) | Ropinirole XL | LTT, Month 63, n=19 | 11.9 | Standard Deviation 7.23 | points on a scale |
| Unified Parkinson's Disease (PD) Rating Scale (UPDRS) Total Activities of Daily Living Scores (Intent-to-Treat Population) | Ropinirole XL | LTT, Month 69, n=20 | 10.8 | Standard Deviation 6.70 | points on a scale |
| Unified Parkinson's Disease (PD) Rating Scale (UPDRS) Total Activities of Daily Living Scores (Intent-to-Treat Population) | Ropinirole XL | LTT, Month 75, n=16 | 12.6 | Standard Deviation 6.66 | points on a scale |
| Unified Parkinson's Disease (PD) Rating Scale (UPDRS) Total Activities of Daily Living Scores (Intent-to-Treat Population) | Ropinirole XL | LTT, Month 78, n=13 | 11.5 | Standard Deviation 6.64 | points on a scale |
| Number of Participants With the Indicated Number of Adverse Events (AEs) | Ropinirole XL | Participants (Par.) with at least one event | 81 | participants | |
| Number of Participants With the Indicated Number of Adverse Events (AEs) | Ropinirole XL | Par. with 0 events | 2 | participants | |
| Number of Participants With the Indicated Number of Adverse Events (AEs) | Ropinirole XL | Par. with 1 event | 1 | participants | |
| Number of Participants With the Indicated Number of Adverse Events (AEs) | Ropinirole XL | Par. with 2 events | 0 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00650104/results